12 citations
,
July 2016 in “Journal of dermatology” This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.
70 citations
,
April 2016 in “Experimental Dermatology” In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.
39 citations
,
April 2016 in “Case Reports in Dermatology” This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.
28 citations
,
January 2016 in “Dermatology” This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.
65 citations
,
December 2015 in “Experimental dermatology” This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
30 citations
,
August 2015 in “JAAD case reports” This case report describes a patient with corticosteroid-resistant ophiasis alopecia areata who experienced prompt hair regrowth after receiving platelet-rich plasma injections.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.
62 citations
,
June 2015 in “The Journal of Dermatology” This study found that patients with alopecia areata had higher levels of Th17 cells and lower levels of regulatory T cells compared to healthy controls, suggesting an immune imbalance in these patients.
5 citations
,
May 2015 in “The Journal of Dermatology” Topical corticosteroids can help treat severe alopecia areata when other treatments fail.
184 citations
,
February 2015 in “EBioMedicine” This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.
44 citations
,
February 2015 in “Journal of the American Academy of Dermatology” This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.
62 citations
,
January 2015 in “Journal of Dermatological Science” This review summarizes the current genetic research on alopecia areata, including potential new therapeutic strategies, but reports no new clinical findings.
16 citations
,
January 2015 in “Current problems in dermatology” This article reviews treatment options and psychological impacts of alopecia areata and reports no new clinical findings.
61 citations
,
January 2015 in “Indian Journal of Plastic Surgery” This study found that platelet-rich plasma may have a role in treating chronic alopecia areata, but more long-term follow-up studies are needed to confirm its effectiveness and success rate.
21 citations
,
December 2014 in “Clinics in dermatology” This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
37 citations
,
October 2014 in “JAMA dermatology” This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
72 citations
,
July 2014 in “American journal of clinical dermatology” This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.
25 citations
,
February 2014 in “British journal of dermatology/British journal of dermatology, Supplement” The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.
71 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.
110 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This article reviews current understanding of alopecia areata, its genetic and immune factors, and discusses ongoing research and treatment development, without presenting new experimental results.
33 citations
,
October 2013 in “Cutaneous and ocular toxicology” This article discusses the autoimmune pathogenesis of alopecia areata and reviews the use of immunosuppressive therapies in its treatment, but it does not provide new clinical results.
205 citations
,
April 2013 in “British Journal of Dermatology” In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.
106 citations
,
January 2013 in “Clinical and Developmental Immunology” This review discusses the pathogenesis of alopecia areata, highlighting the role of immune privilege collapse in hair follicles but reports no clinical results.
21 citations
,
January 2013 in “Annals of dermatology/Annals of Dermatology” In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.
85 citations
,
October 2012 in “Dermatologic Clinics” This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
39 citations
,
January 2012 in “Dermatology” In this study, the combination of pulse intravenous corticosteroids and methotrexate was associated with positive hair regrowth in severe alopecia areata patients, with half achieving total regrowth.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.
109 citations
,
May 2011 in “Dermatologic Therapy” This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.
61 citations
,
September 2010 in “Journal of Dermatological Science” This review discusses the interplay between hormonal and immune systems in hair follicles and reports no new results, highlighting the need for further research on their role in skin biology and alopecia areata.
61 citations
,
June 2010 in “Journal of the European Academy of Dermatology and Venereology” This study highlights cases of alopecia areata that developed during anti-TNF-α therapy, suggesting a potential link or increased frequency, particularly among individuals with a personal or family history of autoimmune diseases.
13 citations
,
June 2010 in “Journal of dermatological treatment” This study found that diphencyprone showed a significant clinical response for treating alopecia areata, while tacrolimus was not effective.
244 citations
,
January 2010 in “Journal of the American Academy of Dermatology” This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.
391 citations
,
January 2010 in “Journal of The American Academy of Dermatology” This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.
50 citations
,
December 2009 in “Journal of The European Academy of Dermatology and Venereology” This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” This study reported that 1% bexarotene gel was well tolerated and possibly effective for inducing partial hair regrowth in alopecia areata, but more rigorous trials are needed to confirm its efficacy.
79 citations
,
September 2009 in “Pediatric dermatology” This study found that the 308-nm Excimer laser was effective and safe for treating patchy alopecia areata in children, with hair regrowth observed in 60% of treated scalp patches.
9 citations
,
April 2009 in “Dermatologic surgery” Infrared light might help treat stubborn alopecia areata.
55 citations
,
March 2009 in “Journal of The American Academy of Dermatology” This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.
45 citations
,
July 2008 in “International Journal of Dermatology” This study found that oral sulfasalazine led to varying hair regrowth outcomes in patients with persistent alopecia areata, with 56.3% showing moderate to good responses.
164 citations
,
April 2008 in “Cochrane library” This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.
26 citations
,
March 2007 in “Clinical and experimental dermatology” Pimecrolimus cream is not effective for treating alopecia areata.
151 citations
,
February 2007 in “International Journal of Dermatology” This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.
69 citations
,
December 2006 in “Archives of dermatology” This entry contains no research abstract, so no scientific findings or conclusions are reported.
63 citations
,
January 2006 in “Journal of cosmetic and laser therapy” This study found that pulsed infrared diode laser therapy (904 nm) was effective in promoting hair regrowth in 94% of patients with resistant patches of alopecia areata.
36 citations
,
November 2005 in “Journal of The American Academy of Dermatology” This article discusses the potential of latanoprost for treating alopecia areata, but notes that well-controlled studies are still needed to confirm its effectiveness.
185 citations
,
August 2005 in “Autoimmunity Reviews” This review discusses alopecia areata as a model for studying tissue-directed autoimmune diseases and reports no new clinical findings.
85 citations
,
November 2004 in “Journal of the American Academy of Dermatology” The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.
105 citations
,
December 1995 in “British journal of dermatology/British journal of dermatology, Supplement” This retrospective study concluded that PUVA treatment is generally ineffective for alopecia areata, with low effective success rates for partialis, totalis, and universalis types.
109 citations
,
November 1987 in “Archives of dermatology” In this study, 0.5%-1.0% anthralin cream led to a cosmetic response in 25% of patients with severe alopecia areata, despite common side effects like pruritus and erythema.